+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Pulmonary Arterial Hypertension Market Research Report by Drug Class, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19

  • ID: 5011141
  • Report
  • July 2021
  • Region: Global
  • 184 pages
  • 360iResearch™
UP TO OFF
until Sep 30th 2021
The Global Pulmonary Arterial Hypertension Market will Grow to USD 10,986.68 Million by 2026, at a CAGR of 6.40%

FEATURED COMPANIES

  • Arena Pharmaceuticals
  • Bayer AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Merck & Co. Inc.
  • MORE
The Global Pulmonary Arterial Hypertension Market size was estimated at USD 7,570.98 Million in 2020 and expected to reach USD 8,030.10 Million in 2021, at a Compound Annual Growth Rate (CAGR) 6.40% to reach USD 10,986.68 Million by 2026.



Market Statistics:


The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:


This research report categorizes the Pulmonary Arterial Hypertension to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Drug Class, the Pulmonary Arterial Hypertension Market was studied across Calcium Channel Blocker, Endothelin Receptor Antagonists, Phosphodiesterase 5, and Prostacyclin & Prostacyclin Analog.
  • Based on Distribution, the Pulmonary Arterial Hypertension Market was studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
  • Based on Region, the Pulmonary Arterial Hypertension Market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:


COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:


The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:


The FPNV Positioning Matrix evaluates and categorizes the vendors in the Pulmonary Arterial Hypertension Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:


The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Company Usability Profiles:


The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Pulmonary Arterial Hypertension Market, including Arena Pharmaceuticals, Bayer AG, Bristol-Myers Squibb Company, Gilead Sciences, Inc., GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co. Inc., Novartis International AG, Pfizer, Inc., and United Therapeutics Corporation.

The report provides insights on the following pointers:


1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:


1. What is the market size and forecast of the Global Pulmonary Arterial Hypertension Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Pulmonary Arterial Hypertension Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Pulmonary Arterial Hypertension Market?
4. What is the competitive strategic window for opportunities in the Global Pulmonary Arterial Hypertension Market?
5. What are the technology trends and regulatory frameworks in the Global Pulmonary Arterial Hypertension Market?
6. What is the market share of the leading vendors in the Global Pulmonary Arterial Hypertension Market?
7. What modes and strategic moves are considered suitable for entering the Global Pulmonary Arterial Hypertension Market?
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Arena Pharmaceuticals
  • Bayer AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Merck & Co. Inc.
  • MORE
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary
3.1. Introduction
3.2. Market Outlook
3.3. Drug Class Outlook
3.4. Distribution Outlook
3.5. Region Outlook
3.6. Competitor Outlook

4. Market Overview
4.1. Introduction
4.2. Cumulative Impact of COVID-19

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of cardiovascular diseases and the growing geriatric population
5.1.1.2. Supportive government initiatives for the development of orphan drugs
5.1.1.3. Clinical drugs in pipeline for pulmonary treatment
5.1.2. Restraints
5.1.2.1. Limited awareness about presence of pulmonary arterial hypertension among patients
5.1.2.2. High diagnosis & treatment cost of pulmonary disorders
5.1.3. Opportunities
5.1.3.1. Advance oral drugs for pulmonary arterial hypertension
5.1.3.2. Technology advancement such as biomaker and new gene therapy for the treatment
5.1.4. Challenges
5.1.4.1. Complicated process of clinical approval of drugs
5.2. Porters Five Forces Analysis
5.2.1. Threat of New Entrants
5.2.2. Threat of Substitutes
5.2.3. Bargaining Power of Customers
5.2.4. Bargaining Power of Suppliers
5.2.5. Industry Rivalry

6. Pulmonary Arterial Hypertension Market, by Drug Class
6.1. Introduction
6.2. Calcium Channel Blocker
6.3. Endothelin Receptor Antagonists
6.4. Phosphodiesterase 5
6.5. Prostacyclin & Prostacyclin Analog

7. Pulmonary Arterial Hypertension Market, by Distribution
7.1. Introduction
7.2. Hospital Pharmacy
7.3. Online Pharmacy
7.4. Retail Pharmacy

8. Americas Pulmonary Arterial Hypertension Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States

9. Asia-Pacific Pulmonary Arterial Hypertension Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Thailand

10. Europe, Middle East & Africa Pulmonary Arterial Hypertension Market
10.1. Introduction
10.2. France
10.3. Germany
10.4. Italy
10.5. Netherlands
10.6. Qatar
10.7. Russia
10.8. Saudi Arabia
10.9. South Africa
10.10. Spain
10.11. United Arab Emirates
10.12. United Kingdom

11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis
11.3. Market Share Analysis, By Key Player
11.4. Competitive Scenario
11.4.1. Merger & Acquisition
11.4.2. Agreement, Collaboration, & Partnership
11.4.3. New Product Launch & Enhancement
11.4.4. Investment & Funding
11.4.5. Award, Recognition, & Expansion

12. Company Usability Profiles
12.1. Arena Pharmaceuticals
12.2. Bayer AG
12.3. Bristol-Myers Squibb Company
12.4. Gilead Sciences, Inc.
12.5. GlaxoSmithKline Plc
12.6. Johnson & Johnson
12.7. Merck & Co. Inc.
12.8. Novartis International AG
12.9. Pfizer, Inc.
12.10. United Therapeutics Corporation

13. Appendix
13.1. Discussion Guide
13.2. License & Pricing

List of Figures
FIGURE 1. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2020 VS 2026 (USD MILLION)
FIGURE 2. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2020 (USD MILLION)
FIGURE 3. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2020 (USD MILLION)
FIGURE 4. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY REGION, 2020 (USD MILLION)
FIGURE 5. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 6. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: MARKET DYNAMICS
FIGURE 7. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: PORTERS FIVE FORCES ANALYSIS
FIGURE 8. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2020 VS 2026 (%)
FIGURE 9. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2020 VS 2026 (USD MILLION)
FIGURE 10. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2026
FIGURE 11. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY CALCIUM CHANNEL BLOCKER, 2018-2026 (USD MILLION)
FIGURE 12. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY CALCIUM CHANNEL BLOCKER, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 13. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ENDOTHELIN RECEPTOR ANTAGONISTS, 2018-2026 (USD MILLION)
FIGURE 14. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ENDOTHELIN RECEPTOR ANTAGONISTS, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 15. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PHOSPHODIESTERASE 5, 2018-2026 (USD MILLION)
FIGURE 16. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PHOSPHODIESTERASE 5, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 17. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PROSTACYCLIN & PROSTACYCLIN ANALOG, 2018-2026 (USD MILLION)
FIGURE 18. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PROSTACYCLIN & PROSTACYCLIN ANALOG, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 19. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2020 VS 2026 (%)
FIGURE 20. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2020 VS 2026 (USD MILLION)
FIGURE 21. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2026
FIGURE 22. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2026 (USD MILLION)
FIGURE 23. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 24. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ONLINE PHARMACY, 2018-2026 (USD MILLION)
FIGURE 25. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 26. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY RETAIL PHARMACY, 2018-2026 (USD MILLION)
FIGURE 27. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 28. AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 29. ARGENTINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 30. BRAZIL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 31. CANADA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 32. MEXICO PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 33. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 34. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 35. AUSTRALIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 36. CHINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 37. INDIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 38. INDONESIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 39. JAPAN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 40. MALAYSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 41. PHILIPPINES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 42. SINGAPORE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 43. SOUTH KOREA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 44. THAILAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 45. EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 46. FRANCE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 47. GERMANY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 48. ITALY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 49. NETHERLANDS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 50. QATAR PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 51. RUSSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 52. SAUDI ARABIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 53. SOUTH AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 54. SPAIN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 55. UNITED ARAB EMIRATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 56. UNITED KINGDOM PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 57. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: FPNV POSITIONING MATRIX
FIGURE 58. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: SHARE, BY KEY PLAYER, 2020
FIGURE 59. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET, BY TYPE

List of Tables
TABLE 1. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016–2020
TABLE 3. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 4. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD MILLION)
TABLE 5. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY CALCIUM CHANNEL BLOCKER, BY REGION, 2018-2026 (USD MILLION)
TABLE 6. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ENDOTHELIN RECEPTOR ANTAGONISTS, BY REGION, 2018-2026 (USD MILLION)
TABLE 7. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PHOSPHODIESTERASE 5, BY REGION, 2018-2026 (USD MILLION)
TABLE 8. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PROSTACYCLIN & PROSTACYCLIN ANALOG, BY REGION, 2018-2026 (USD MILLION)
TABLE 9. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2026 (USD MILLION)
TABLE 10. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2026 (USD MILLION)
TABLE 11. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2026 (USD MILLION)
TABLE 12. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2026 (USD MILLION)
TABLE 13. AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 14. ARGENTINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 15. BRAZIL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 16. CANADA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 17. MEXICO PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 18. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 19. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 20. AUSTRALIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 21. CHINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 22. INDIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 23. INDONESIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 24. JAPAN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 25. MALAYSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 26. PHILIPPINES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 27. SINGAPORE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 28. SOUTH KOREA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 29. THAILAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 30. EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 31. FRANCE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 32. GERMANY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 33. ITALY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 34. NETHERLANDS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 35. QATAR PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 36. RUSSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 37. SAUDI ARABIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 38. SOUTH AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 39. SPAIN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 40. UNITED ARAB EMIRATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 41. UNITED KINGDOM PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 42. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: SCORES
TABLE 43. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: BUSINESS STRATEGY
TABLE 44. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: PRODUCT SATISFACTION
TABLE 45. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: RANKING
TABLE 46. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: SHARE, BY KEY PLAYER, 2020
TABLE 47. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: MERGER & ACQUISITION
TABLE 48. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 49. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 50. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: INVESTMENT & FUNDING
TABLE 51. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 52. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: LICENSE & PRICING
Note: Product cover images may vary from those shown
  • Arena Pharmaceuticals
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Novartis International AG
  • Pfizer, Inc.
  • United Therapeutics Corporation
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll